Medicare (CMS) Local Coverage Determination (LCD) Updates – May 2021

Medicare (CMS) Local Coverage Determination (LCD) Updates »

May 2021 Medicare (CMS) LCD Updates:

• DL37725                                                    MolDX: Melanoma Risk Stratification Molecular Testing
• DL38966                                                    MolDX: Next-Generation Sequencing Lab-Developed Tests for Inherited Cancer Syndromes
• DL38988                                                    MolDX: Multiplex Nucleic Acid Amplification Test (NAAT) Panels for Infectious Disease Testing
• DL38985                                                    MolDX: Biomarkers to Risk-Stratify Patients at Increased Risk for Prostate Cancer
• DL34869                                                    Repetitive Transcranial Magnetic Stimulation (rTMS) in Adults
• DL38970                                                    Advance Care Planning
• DL38994                                                    Epidural Procedures for Pain Management
• DL39017                                                    MolDX: Next-Generation Sequencing Lab-Developed Tests for Inherited Cancer Syndromes
• L34411                                                       Blepharoplasty, Eyelid Surgery, and Brow Lift
• DL37725                                                    MolDX: Melanoma Risk Stratification Molecular Testing
• DL38966                                                    MolDX: Next-Generation Sequencing Lab-Developed Tests for Inherited Cancer Syndromes
• DL38988                                                    MolDX: Multiplex Nucleic Acid Amplification Test (NAAT) Panels for Infectious Disease Testing
• DL38985                                                    MolDX: Biomarkers to Risk-Stratify Patients at Increased Risk for Prostate Cancer
• DL34869                                                    Repetitive Transcranial Magnetic Stimulation (rTMS) in Adults
• DL38970                                                    Advance Care Planning
• DL38994                                                    Epidural Procedures for Pain Management
• DL39017                                                    MolDX: Next-Generation Sequencing Lab-Developed Tests for Inherited Cancer Syndromes
• L34411                                                       Blepharoplasty, Eyelid Surgery, and Brow Lift
• DL39003                                                    MolDX: Multiplex Nucleic Acid Amplification Test (NAAT) Panels for Infectious Disease Testing
• A56963                                                      Billing and Coding: MolDX: EndoPredict Breast Cancer Gene Expression Test
• L38671                                                       MolDX: Molecular Testing for Solid Organ Allograft Rejection
• DL39001                                                    MolDX: Multiplex Nucleic Acid Amplification Test (NAAT) Panels for Infectious Disease Testing
• L38629                                                       MolDX: Molecular Testing for Solid Organ Allograft Rejection
• L37264                                                       MolDX: EndoPredict Breast Cancer Gene Expression Test
• A58170                                                      Billing and Coding: MolDX: Molecular Testing for Solid Organ Allograft Rejection
• A58696                                                      Response to Comments: MolDX: EndoPredict Breast Cancer Gene Expression Test
• A58168                                                      Billing and Coding: MolDX: Molecular Testing for Solid Organ Allograft Rejection
• L37356                                                       MolDX: EndoPredict Breast Cancer Gene Expression Test
• A56997                                                      Billing and Coding: MolDX: EndoPredict Breast Cancer Gene Expression Test
• A58708                                                      Response to Comments: MolDX: EndoPredict Breast Cancer Gene Expression Test
• A58780                                                      Response to Comments: MolDX: Molecular Testing for Solid Organ Allograft Rejection
• L38645                                                       MolDX: Phenotypic Biomarker Detection from Circulating Tumor Cells
• L38643                                                       MolDX: Phenotypic Biomarker Detection from Circulating Tumor Cells
• A58782                                                      Response to Comments: MolDX: Phenotypic Biomarker Detection from Circulating Tumor Cells
• A58185                                                      Billing and Coding: MolDX: Phenotypic Biomarker Detection from Circulating Tumor Cells
• A58778                                                      Response to Comments: MolDX: Molecular Testing for Solid Organ Allograft Rejection
• A58781                                                      Response to Comments: MolDX: Phenotypic Biomarker Detection from Circulating Tumor Cells
• A58183                                                      Billing and Coding: MolDX: Phenotypic Biomarker Detection from Circulating Tumor Cells
• A52603                                                      Administration of Certain Biological Response Modifiers
• DL38974                                                    MolDX: Next-Generation Sequencing Lab-Developed Tests for Inherited Cancer Syndromes
• DL38972                                                    MolDX: Next-Generation Sequencing Lab-Developed Tests for Inherited Cancer Syndromes
• A56973                                                      Billing and Coding: MolDX: Molecular Diagnostic Tests (MDT)
• A56853                                                      Billing and Coding: MolDX: Molecular Diagnostic Tests (MDT)
• A56851                                                      Billing and Coding: MolDX: Multiplex Nucleic Acid Amplified Tests for Respiratory Viral Panels
• A57773                                                      Billing and Coding: MolDX: Breast Cancer Index® (BCI) Gene Expression Test
• DL39007                                                    MolDX: Biomarkers to Risk-Stratify Patients at Increased Risk for Prostate Cancer
• DL39005                                                    MolDX: Biomarkers to Risk-Stratify Patients at Increased Risk for Prostate Cancer
• A56686                                                      Billing and Coding: HbA1c
• DL38301                                                    Micro-Invasive Glaucoma Surgery (MIGS)
• DL38299                                                    Micro-Invasive Glaucoma Surgery (MIGS)
• A56769                                                      Billing and Coding: Somatosensory Testing
• DL37748                                                    MolDX: Melanoma Risk Stratification Molecular Testing
• DL37750                                                    MolDX: Melanoma Risk Stratification Molecular Testing
• A57307                                                      Billing and Coding: Nerve Conduction Studies and Electromyography
• DL39044                                                    MolDX: Multiplex Nucleic Acid Amplification Test (NAAT) Panels for Infectious Disease Testing
• DL39042                                                    MolDX: Biomarkers to Risk-Stratify Patients at Increased Risk for Prostate Cancer
• DL39040                                                    MolDX: Next-Generation Sequencing Lab-Developed Tests for Inherited Cancer Syndromes
• L37663                                                       MolDX: EndoPredict® Breast Cancer Gene Expression Test
• A58752                                                      Response to Comments: MolDX: EndoPredict® Breast Cancer Gene Expression Test
• A57567                                                      Billing and Coding: MolDX: EndoPredict® Breast Cancer Gene Expression Test
• DL38018                                                    MolDX: Melanoma Risk Stratification Molecular Testing

Medicare (CMS) Local Coverage Determination (LCD) Updates »

Policy Alerts monitors Commercial and Medicare (CMS) medical policies for changes. While medical Insurance carriers typically update medical policies annually, there are many reasons why they might review or update a policy. When reviews occur out of cycle they often go unnoticed. Policy Alerts keeps you updated when Payers make coverage changes to medical policies affecting your business.

Policy Alerts continuously monitors Commercial and Medicare Payer coverage information to keep you up-to-date on medical Insurance decisions in real-time. When changes occur, instant email alerts are delivered to your inbox. Clients have access to detailed coverage reports and medical policies through the interactive Policy Alerts Dashboard portal. Save time each month and keep focused on important Payer medical policy reviews and coverage decisions affecting your business!

Policy Alerts takes a client-focused hands-on approach and is constantly working to provide our customers with helpful insights and actionable analytics. We understand what our clients need and are dedicated to providing timely, accurate, and always up-to-date reports.

Health economic and reimbursement information provided by Policy Alerts is gathered from third-party sources and is subject to change without notice as a result of complex and frequently changing laws, regulations, rules and policies. All product and company names are trademarks™ or registered® trademarks of their respective holders. Use of them does not imply any affiliation with or endorsement by them. This information is presented for illustrative purposes only and does not constitute reimbursement or legal advice.